ISIS 757456

DRUG2 trials

Sponsors

Ionis Pharmaceuticals, Inc.

Conditions

HypertensionMild Hypertension

Phase 2

A Study to Assess the Safety, Tolerability and Efficacy of IONIS-AGT-LRx, an Antisense Inhibitor Administered Subcutaneously to Hypertensive Participants With Controlled Blood Pressure

CompletedNCT03714776

Ionis Pharmaceuticals, Inc.Mild Hypertension

Start: 2019-01-03End: 2019-11-13Updated: 2023-01-06

A Study to Assess the Safety, Tolerability and Efficacy of IONIS-AGT-LRx

CompletedNCT04083222

Ionis Pharmaceuticals, Inc.Hypertension

Start: 2019-11-13End: 2020-07-20Updated: 2023-01-18

Related Papers

Antisense Inhibition of Angiotensinogen With IONIS-AGT-L<sub>Rx</sub>: Results of Phase 1 and Phase 2 Studies.

2021-05-0352 citations